Nucleus Biologics
Private Company
Total funding raised: $11M
Overview
Nucleus Biologics is a specialized service and product provider supporting the advanced therapy medicinal product (ATMP) industry, particularly cell and gene therapy developers. The company focuses on the formulation, development, and supply of custom cell culture media and process liquids, which are critical yet complex components in biomanufacturing. By offering tailored solutions and acting as a strategic partner, Nucleus Biologics helps clients reduce development timelines and mitigate supply chain risks. Its business model is centered on providing essential services and consumables to therapeutic developers rather than developing its own drug pipeline.
Technology Platform
Custom cell culture media formulation and development platform, including analytical testing, dual-supply chain management, and fill-finish services for GMP manufacturing.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Nucleus Biologics competes with large, integrated life science tools companies (e.g., Thermo Fisher, Sartorius) that offer off-the-shelf media, as well as other specialized media formulation boutiques. Its differentiation lies in deep customization, client partnership, and a focus on mitigating supply chain risk for critical GMP materials.